drugset / Trial / NCT02398396

Investigating Meningococcal Vaccines in Adults

NCT02398396

Completed 15 enrolled University of Oxford
NaSingle-groupOpen-labelBasic science

Summary

This study will be an open label, exploratory immunogenicity study conducted by the Oxford Vaccine Group, University of Oxford. This study will investigate the breadth of protective activity of serum anti-FHbp antibody responses of adults immunized with 4CMenB (Bexsero®) vaccine as well as investigating the nature of the B-cell and T-cell responses induced by vaccination. The investigators aim to enroll 15 to 20 healthy adults aged 18 to 60, who will be immunized with two doses of 4CMenB (Bexsero®) two months apart according to the licensed schedule. Blood samples will be obtained at baseline and after each dose of vaccine.

Timeline

Start
2015-04
Primary completion
2015-11
Completion
2019-06-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Bexsero Vaccine 0.5 ml Intramuscular